Save on Gamma Irradiation

Once platelets undergo pathogen inactivation with the INTERCEPT™ Blood System, there is no further need for gamma irradiation to prevent transfusion-associated graft versus host disease (TA-GVHD).

‘50% of TA-GVHD cases occur in patients who would not be predicted to be at risk for TA-GVHD by current guidelines for blood irradiation’.

Kopolovic I, et al., A systematic review of transfusion-associated graft versus host disease, Blood (2015) 126, 406-414

Pathogen inactivation with the INTERCEPT™ Blood System eliminates the risk of TA-GVHD in 100% of transfused patients in published haemovigilance studies.¹

The incremental purchase cost for gamma-irradiated platelets, and the cost for transfusion-associated adverse events due to the transfusion of non-gamma-irradiated blood components to patients at risk for TA-GVHD, can be avoided with the INTERCEPT Blood System.

Source:

1.F. Knutson, A prospective, active haemovigilance study with combined cohort analysis of 19.175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.